How to Get Wegovy on NHS UK 2026? Eligibility and Access

Getting access to Wegovy through the NHS can feel like navigating a maze, and you are certainly not alone if you have found yourself confused about whether you qualify and how to actually obtain this weight loss medication. Since Wegovy became available in the UK, thousands of people have been searching for clear answers about NHS eligibility criteria, waiting times, and what happens if they do not meet the strict requirements. This comprehensive guide breaks down everything you need to know about accessing Wegovy through the NHS, explains the eligibility criteria in plain English, and explores alternative routes if the NHS pathway is not available to you.

Quick Summary

Wegovy (semaglutide 2.4mg) is now available on the NHS for eligible patients, but access involves meeting strict criteria and navigating specialist weight management services. Understanding the requirements upfront can save you time and help you explore all available options.

• NHS eligibility typically requires a BMI of 35+ with a weight-related health condition, or BMI 30+ for certain ethnic groups
• Wegovy must be initiated through specialist weight management services, not directly by your GP
• Waiting times for NHS weight management services can range from 6 months to over 2 years
• Private pharmacy routes offer an alternative for those who do not meet NHS criteria or cannot wait
• Lifestyle changes including diet and exercise must accompany Wegovy treatment regardless of access route

Table of Contents

• What Is Wegovy and Why Is It Prescribed on the NHS
• NHS Wegovy Eligibility Criteria Explained
• How to Access Wegovy Through Your GP and NHS Services
• Current NHS Waiting Times and Regional Variations
• Alternative Routes If NHS Access Is Not Available
• NHS vs Private Wegovy Access Comparison
• Key Takeaways
• When to Seek Professional Advice
• Frequently Asked Questions

What Is Wegovy and Why Is It Prescribed on the NHS

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally developed for managing type 2 diabetes before researchers discovered its significant weight loss benefits. The medication works by mimicking a natural hormone that regulates appetite and food intake, helping people feel fuller for longer and reducing the urge to eat. Unlike older weight loss medications that often came with concerning side effects or limited effectiveness, Wegovy has demonstrated substantial and sustained weight loss in clinical trials, which led to its approval for chronic weight management.

The National Institute for Health and Care Excellence (NICE) approved Wegovy for NHS use in March 2023, recognising obesity as a chronic disease that requires medical intervention alongside lifestyle changes. This was a significant shift in how the NHS approaches weight management, acknowledging that willpower alone is often insufficient for people struggling with significant obesity. The approval means that eligible patients can now access this treatment through the NHS at no cost, though the pathway to obtaining it involves specific criteria and specialist assessment.

Wegovy is administered as a once-weekly injection that patients can give themselves at home after proper training. The treatment follows a dose escalation schedule, starting at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg over approximately 16 weeks. This gradual approach helps minimise side effects and allows the body to adjust to the medication. Clinical trials have shown that patients taking Wegovy alongside lifestyle interventions can achieve average weight loss of around 15% of their body weight, which is significantly higher than what most people achieve through diet and exercise alone.

• Wegovy is a once-weekly injectable medication containing semaglutide 2.4mg
• NICE approved Wegovy for NHS use in England in March 2023
• The medication works by reducing appetite and helping people feel satisfied with less food
• Clinical trials showed average weight loss of approximately 15% of body weight
• Treatment requires gradual dose increases over 16 weeks to reach the maintenance dose

NHS Wegovy Eligibility Criteria Explained

Understanding the eligibility criteria for NHS Wegovy is crucial because many people assume they will automatically qualify based on their BMI alone, only to discover that the requirements are more nuanced than expected. The NICE guidelines set out specific criteria that must be met, and these criteria exist to ensure the medication is prescribed to those who will benefit most while managing NHS resources effectively. If you are wondering why Wegovy is not working for some patients, understanding the complete eligibility picture is essential.

The primary eligibility requirement centres on Body Mass Index combined with the presence of weight-related health conditions. For most adults, the threshold is a BMI of 35 or above alongside at least one weight-related comorbidity such as type 2 diabetes, prediabetes, hypertension, cardiovascular disease, dyslipidaemia, or obstructive sleep apnoea. However, the NHS recognises that certain ethnic groups face increased health risks at lower BMI levels, so the threshold is reduced to BMI 32.5 or above for people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean background. Some clinical commissioning groups may apply a lower threshold of BMI 30 in specific circumstances.

Beyond BMI requirements, NICE guidelines stipulate that Wegovy should only be prescribed within specialist weight management services, not directly by GPs. This means patients must first be referred to and assessed by a specialist team before treatment can begin. The specialist service will evaluate whether the patient has already attempted lifestyle interventions, whether there are any contraindications to treatment, and whether the patient is likely to adhere to the required lifestyle modifications that must accompany medication use. Additionally, NHS funding for Wegovy is typically limited to a maximum treatment duration of two years, after which patients must demonstrate sustained engagement with lifestyle changes.

There are also specific exclusion criteria that will prevent NHS Wegovy access. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 cannot take Wegovy. The medication is contraindicated during pregnancy and breastfeeding, and women of childbearing age must use effective contraception. Patients with a history of pancreatitis, severe gastrointestinal disease, or end-stage renal disease may also be excluded or require additional assessment before treatment can be considered.

• Standard eligibility requires BMI 35+ with at least one weight-related health condition
• Lower BMI thresholds (32.5 or 30) apply for certain ethnic groups at higher risk
• Treatment must be initiated through specialist weight management services
• Previous lifestyle intervention attempts are typically required before medication is offered
• Maximum NHS-funded treatment duration is usually limited to two years
• Certain medical conditions including thyroid cancer history are strict contraindications

How to Access Wegovy Through Your GP and NHS Services

The journey to obtaining Wegovy on the NHS begins with a conversation with your GP, though it is important to understand that your GP cannot prescribe Wegovy directly. Instead, your GP acts as the gateway to specialist weight management services where the actual prescribing decision is made. When you book your appointment, be prepared to discuss your weight history, previous weight loss attempts, any weight-related health conditions you have, and your motivation for seeking medical treatment. Bringing a record of your weight over time and any previous diet or exercise programmes you have tried can help demonstrate your commitment and history.

If your GP agrees that you may be eligible, they will make a referral to your local Tier 3 specialist weight management service. These services are typically based in hospital outpatient departments or community health centres and are staffed by multidisciplinary teams including obesity physicians, dietitians, psychologists, and specialist nurses. The referral process varies significantly between NHS trusts, and in some areas, there may be intermediate Tier 2 services that you must complete before being eligible for Tier 3 referral. Your GP can explain the specific pathway in your area, as these arrangements differ considerably across England.

Once referred, you will receive an appointment with the specialist weight management service for an initial assessment. This assessment is comprehensive and will examine your physical health, mental health, eating behaviours, activity levels, and any barriers to weight loss you have experienced. The team will discuss all available treatment options with you, which may include intensive dietary programmes, behavioural therapy, pharmacotherapy including Wegovy, or bariatric surgery for those who meet the criteria. The decision to prescribe Wegovy will depend on your individual circumstances and whether the team believes it is the most appropriate intervention for you.

If Wegovy is prescribed, the specialist service will provide training on how to administer the injection and monitor your progress during the dose escalation phase. Follow-up appointments will assess your response to treatment, manage any side effects, and ensure you are making the required lifestyle changes. The requirements for similar medications like Mounjaro follow comparable pathways, so understanding this process helps with any GLP-1 treatment.

• Start by booking a GP appointment to discuss weight management options
• Your GP will refer you to local Tier 3 specialist weight management services
• Initial specialist assessment examines physical health, mental health, and eating behaviours
• The specialist team decides whether Wegovy is appropriate for your situation
• If prescribed, you will receive training and regular monitoring appointments
• Ongoing lifestyle support is provided alongside medication throughout treatment

Current NHS Waiting Times and Regional Variations

One of the most significant barriers to accessing Wegovy on the NHS is the substantial waiting times that many patients face. Specialist weight management services across England are experiencing unprecedented demand, partly due to increased awareness of obesity treatments and partly due to service capacity that has not kept pace with need. Current waiting times vary dramatically depending on where you live, with some areas reporting waits of 6 to 12 months while others have waiting lists extending beyond two years. This postcode lottery means that your chances of accessing timely treatment depend heavily on your geographical location.

The disparity in waiting times reflects broader inequalities in NHS service provision for obesity. Some Integrated Care Boards have invested heavily in weight management services and have relatively short waiting times, while others have limited capacity and long waiting lists. Additionally, the availability of Wegovy itself has been affected by supply issues since its launch, with Novo Nordisk implementing supply restrictions to ensure existing patients can continue their treatment before new patients are started. These supply constraints have added another layer of uncertainty to an already challenging access pathway.

If you are facing long waiting times, there are several steps you can take while you wait. Your GP can prescribe other weight loss medications such as orlistat or refer you to Tier 2 weight management services for group-based lifestyle support. Many NHS trusts also offer digital weight management programmes that can help you make progress while waiting for specialist assessment. Staying engaged with weight management during this waiting period can actually improve your outcomes once you do access specialist services, and documented efforts at lifestyle change may strengthen your case for medication when you are eventually assessed.

Understanding that waiting times exist should not discourage you from pursuing NHS access if you believe you are eligible. Starting the referral process early means you will be in the queue, and for those who genuinely cannot wait due to health concerns, alternative private options exist. However, be cautious of any service that promises to fast-track NHS access, as the eligibility criteria and referral pathways are standardised and cannot be bypassed through private payments within the NHS system.

• NHS waiting times for specialist weight management range from 6 months to over 2 years
• Waiting times vary significantly between different regions and NHS trusts
• Supply restrictions on Wegovy have added additional delays in some areas
• Alternative treatments and lifestyle programmes may be available while you wait
• Starting the referral process early ensures you are in the queue for assessment
• Private options exist for those who cannot wait for NHS access

Alternative Routes If NHS Access Is Not Available

For many people, the combination of strict eligibility criteria and long waiting times means that NHS access to Wegovy simply is not a realistic option. This can be incredibly frustrating, particularly if you are struggling with your weight and feel that medical intervention could help. Fortunately, alternative routes exist that can provide access to Wegovy and other effective weight loss treatments, though these come with associated costs that you will need to consider. The weight loss treatments available through regulated pharmacies offer legitimate alternatives to NHS pathways.

Registered online pharmacies and prescribing services can provide Wegovy through private prescriptions for patients who meet the clinical criteria but do not qualify for or cannot access NHS provision. These services employ prescribers who assess your suitability for treatment through detailed questionnaires and often video consultations. The eligibility criteria for private prescriptions may be slightly different from NHS criteria, with some services prescribing to patients with lower BMI levels provided they have risk factors or have struggled with weight management. However, reputable services will still require evidence of health conditions and will not prescribe to anyone regardless of circumstances.

The cost of private Wegovy treatment is substantial, with monthly costs typically ranging from £150 to £300 depending on the dose and supplier. This cost covers the medication itself, and some services charge additional fees for consultations and monitoring. Before committing to private treatment, ensure you are using a pharmacy registered with the General Pharmaceutical Council (GPhC) and that prescribing decisions are made by appropriately qualified healthcare professionals. Be wary of services offering unusually low prices or making claims that seem too good to be true, as counterfeit or improperly stored medications pose serious health risks.

If Wegovy is not accessible or affordable, other GLP-1 medications may be available through similar private routes. Mounjaro containing tirzepatide is another highly effective weight loss medication that works through similar mechanisms. Understanding how long Mounjaro takes to work can help you make informed decisions about alternative treatments. Saxenda, another GLP-1 medication, may be available through some NHS services with different eligibility criteria, or can be obtained privately at generally lower cost than Wegovy.

• Private pharmacy services can prescribe Wegovy to eligible patients outside the NHS
• Private treatment costs typically range from £150 to £300 per month
• Always use GPhC-registered pharmacies and qualified prescribers
• Alternative GLP-1 medications like Mounjaro or Saxenda may be available
• Some private services have broader eligibility criteria than the NHS
• Beware of counterfeit medications from unregistered sources

NHS vs Private Wegovy Access Comparison

Choosing between NHS and private access to Wegovy involves weighing multiple factors including cost, waiting times, eligibility criteria, and ongoing support. The following table provides a comprehensive comparison to help you understand what each pathway offers and make an informed decision about which route might be most appropriate for your circumstances.

Factor	NHS Access	Private Pharmacy Access
Cost to Patient	Free at point of use (standard NHS prescription charges may apply)	£150-£300 per month plus consultation fees
BMI Eligibility	35+ with comorbidity, or 32.5+/30+ for certain ethnic groups	Typically 30+ with risk factors (varies by provider)
Waiting Time	6 months to 2+ years depending on location	Usually within 1-2 weeks of assessment
Prescriber	Specialist weight management service clinician	Registered prescriber (GP, nurse prescriber, or pharmacist)
Initial Assessment	Comprehensive face-to-face specialist assessment	Online questionnaire and/or video consultation
Lifestyle Support	Multidisciplinary team including dietitian and psychologist	Varies by provider; some offer minimal support
Treatment Duration Limit	Typically maximum 2 years NHS funding	No fixed limit; continues as long as clinically appropriate
Monitoring	Regular specialist appointments throughout treatment	Varies; may be less intensive than NHS pathway
Supply Continuity	May be affected by NHS supply arrangements	Provider manages supply directly
Geographic Availability	Varies significantly by NHS trust area	Available nationwide through online services

Key Takeaways

• NHS Wegovy eligibility requires BMI 35+ with weight-related health conditions, or lower thresholds for certain ethnic groups, combined with referral to specialist weight management services
• Waiting times for NHS specialist services vary dramatically by location and can extend beyond two years, making early referral essential if you wish to pursue this route
• Your GP cannot prescribe Wegovy directly but plays a crucial role in assessing eligibility and making referrals to appropriate specialist services
• Private pharmacy options provide faster access for those who do not meet NHS criteria or cannot wait, though costs range from £150-£300 monthly
• Whichever access route you choose, Wegovy must be combined with lifestyle changes including improved diet and increased physical activity for optimal results

When to Seek Professional Advice

While this guide provides comprehensive information about accessing Wegovy, certain situations require direct consultation with healthcare professionals. You should speak to your GP urgently if you are experiencing health complications related to your weight such as difficulty breathing, joint pain affecting mobility, or symptoms of type 2 diabetes including increased thirst and frequent urination. These conditions may require immediate medical attention regardless of whether you are pursuing weight loss medication.

If you are already taking Wegovy through any route and experience concerning side effects, seek medical advice promptly. Symptoms that require urgent attention include severe abdominal pain that does not resolve, persistent vomiting that prevents you keeping fluids down, signs of allergic reaction such as facial swelling or difficulty breathing, or significant changes in vision. While most side effects of Wegovy are mild and temporary, serious complications can occur and should never be ignored.

Mental health considerations are also important when pursuing weight loss treatment. If you notice changes in mood, increased anxiety, or thoughts of self-harm while taking Wegovy or while waiting for treatment, speak to a healthcare professional immediately. Weight management is a complex journey that affects both physical and psychological wellbeing, and appropriate support should be available throughout. Your GP or the specialist weight management team can arrange referrals to mental health services if needed.

Frequently Asked Questions

Can I get Wegovy free on the NHS?

Wegovy is available free on the NHS for